Risk-benefit profile of onasemnogene abeparvovec in older and heavier children with spinal muscular atrophy type 1
Neuromuscular Disorders · 2024
DOI: 10.1016/j.nmd.2024.07.004 ↗Kurz gefasst
Fallbericht in der Zeitschrift Neuromuscular Disorders, 2024. Verfasst von Rebecca Finnegan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health & Great Ormond Street Hospital, London, UK. Electronic address: rebe…. Hauptthemen laut MEDLINE: Spinal Muscular Atrophies of Childhood, Biological Products, Genetic Therapy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Spinal muscular atrophy (SMA) is an autosomal recessive disorder with progressive muscle atrophy and weakness, caused by biallelic mutations in the survival motor neuron 1 (SNM1) gene. Onasemnogene abeparvovec (OA) is an approved gene replacement therapy for patients with SMA. We report on two patients with SMA type 1, weighing 20 kg, previously treated with Nusinersen, who received OA infusion at 7 years of age. To our knowledge, these two patients are the heaviest treated in the real-world and we describe their different courses after gene therapy, including liver impairment requiring long-term steroid treatment and additional immunosuppression, with only transitory improvement in functional outcomes. Our cases illustrate how careful risk-benefit consideration is required in treating older and heavier SMA patients with OA, especially in view of the multiple treatment choices available for older patients with SMA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health & Great Ormond Street Hospital, London, UK. Electronic address: rebecca.finnegan@gosh.nhs.uk.
- Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health & Great Ormond Street Hospital, London, UK.
- Paediatric Liver Service, King's College Hospital, London, UK.
- Department of Paediatric Neurology, University Hospital Bristol, Bristol, United Kingdom.
- Children's Neurosciences, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
- Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health & Great Ormond Street Hospital, London, UK; NIHR Great Ormond Street Hospital Biomedical Research Centre, London, UK.
Zitieren
APA
Finnegan, R., Manzur, A., Munot, P., Dhawan, A., Murugan, A., Majumdar, A., Wraige, E., Gowda, V., Vanegas, M., Main, M., O'Reilly, E., Baranello, G., Muntoni, F., & Scoto, M. (2024). Risk-benefit profile of onasemnogene abeparvovec in older and heavier children with spinal muscular atrophy type 1. Neuromuscular Disorders. https://doi.org/10.1016/j.nmd.2024.07.004
Vancouver
Finnegan R, Manzur A, Munot P, Dhawan A, Murugan A, Majumdar A, et al. Risk-benefit profile of onasemnogene abeparvovec in older and heavier children with spinal muscular atrophy type 1. Neuromuscular Disorders. 2024. doi:10.1016/j.nmd.2024.07.004
BibTeX
@article{Finnegan2024,
author = {Finnegan, Rebecca and Manzur, Adnan and Munot, Pinki and Dhawan, Anil and Murugan, Archana and Majumdar, Anirban and Wraige, Elizabeth and Gowda, Vasantha and Vanegas, Maria and Main, Marion and O'Reilly, Emer and Baranello, Giovanni and Muntoni, Francesco and Scoto, Mariacristina},
title = {Risk-benefit profile of onasemnogene abeparvovec in older and heavier children with spinal muscular atrophy type 1},
journal = {Neuromuscular Disorders},
year = {2024},
doi = {10.1016/j.nmd.2024.07.004}
}
EUVIMED